Compare ZIM & ADPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ZIM | ADPT |
|---|---|---|
| Founded | 1945 | 2009 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.2B | 3.0B |
| IPO Year | 2020 | 2019 |
| Metric | ZIM | ADPT |
|---|---|---|
| Price | $24.92 | $17.46 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 9 |
| Target Price | ★ $19.26 | $17.78 |
| AVG Volume (30 Days) | 994.3K | ★ 2.1M |
| Earning Date | 05-20-2026 | 05-05-2026 |
| Dividend Yield | ★ 7.65% | N/A |
| EPS Growth | N/A | ★ 63.89 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $276,976,000.00 |
| Revenue This Year | N/A | $3.98 |
| Revenue Next Year | N/A | $22.72 |
| P/E Ratio | $3.49 | ★ N/A |
| Revenue Growth | N/A | ★ 54.77 |
| 52 Week Low | $12.33 | $9.96 |
| 52 Week High | $29.97 | $20.76 |
| Indicator | ZIM | ADPT |
|---|---|---|
| Relative Strength Index (RSI) | 46.66 | 61.59 |
| Support Level | $22.93 | $14.87 |
| Resistance Level | $27.08 | $17.72 |
| Average True Range (ATR) | 0.78 | 1.27 |
| MACD | 0.13 | 0.24 |
| Stochastic Oscillator | 63.39 | 65.89 |
ZIM Integrated Shipping Services Ltd is an asset-light container liner shipping company. It offers tailored services, including land transportation and logistical services, specialized shipping solutions, including the transportation of out-of-gauge cargo, refrigerated cargo, and dangerous and hazardous cargo. Its services include Cargo Services, Digital Services, Schedules, and Shipping Trades and Lines. Geographically, it derives a majority of its revenue from the Pacific trade region.
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers. The company has two operating segments: Minimal Residual Disease and Immune Medicine. The company generates the majority of its revenue from the Minimal Residual Disease segment.